Editorials

2729 Age, eGFR, and CKD Complications  
Jean L. Holley  
See related article on pages 2822.

2732 Influence of Reporting Methods of Outcomes across Transplant Centers  
Akinlolu O. Ojo  
See related article on page 2838.

2735 FGF23 Beyond Mineral Metabolism: A Bridge to Cardiovascular Disease  
Tobias E. Larsson  
See related article on page 2871.

2738 Lipoprotein Subfractions and Particle Size in End-Stage Renal Disease  
Peter A. McCullough, Fawaz Al-Ejel, and Robert C. Maynard  
See related article on page 2861.

Original Articles

Acute Kidney Injury/Acute Renal Failure

2740 Risk of Poor Outcomes with Novel and Traditional Biomarkers at Clinical AKI Diagnosis  
Isaac E. Hall, Steven G. Coca, Mark A. Perazella, Umo U. Eko, Randy L. Luciano, Patricia R. Peter, Won K. Han, and Chirag R. Parikh

Chronic Kidney Disease

2750 Echocardiographic Parameters are Independently Associated with Rate of Renal Function Decline and Progression to Dialysis in Patients with Chronic Kidney Disease  
Szu-Chia Chen, Ho-Ming Su, Chi-Chih Hung, Jer-Ming Chang, Wan-Chun Liu, Jer-Chia Tsai, Ming-Yen Lin, Shang-Jyh Hwang, and Hung-Chun Chen

2759 Prevalence and Correlates of Multiple Cardiovascular Risk Factors in Children with Chronic Kidney Disease  
Amy C. Wilson, Michael F. Schneider, Christopher Cox, Larry A. Greenbaum, Jeffrey Saland, Colin T. White, Susan Furth, Bradley A. Warady, and Mark M. Mitsnefes

2766 Characterization of a Recurrent In-frame UMOD Indel Mutation Causing Late-onset Autosomal Dominant End-Stage Renal Failure  
Graham D. Smith, Caroline Robinson, Andrew P. Stewart, Emily L. Edwards, Hannah I. Karet, Anthony G. W. Norden, Richard N. Sandford, and Fiona E. Karet Frankl

2775 Profiling of Autoantibodies in IgA Nephropathy, an Integrative Antibiotics Approach  
Tara K. Sigdel, Sang Hoon Woo, Hong Dai, Purvesh Khatri, Li Li, Bryan Myers, Minnie M. Sarwal, and Richard A. Lafayette

2785 Inverse Relationship between the Inflammatory Marker Pentraxin-3, Fat Body Mass, and Abdominal Obesity in End-Stage Renal Disease  
Tetsu Miyamoto, Abdul Rashid Qureshi, Olof Heimburger, Peter Bárány, Karin Carrero, Bodil Sjöberg, Bengt Lindholm, Peter Stenvinkel, and Juan Jesús Carrero
Clinical Nephrology

2799 Contaminated Cocaine and Antineutrophil Cytoplasmic Antibody-Associated Disease
Martina M. McGrath, Tamara Isakova, Helmut G. Rennke, Ann M. Mottola, Karen A. Laliberte, and John L. Niles

2806 Validation Study of Oxford Classification of IgA Nephropathy: The Significance of Extracapillary Proliferation
Ritsuko Katafuchi, Toshiharu Ninomiya, Masaharu Nagata, Koji Mitsuiki, and Hideki Hirakata

2814 The Anion Gap and Routine Serum Protein Measurements in Monoclonal Gammopathies

Epidemiology and Outcomes

2822 Age-Specific Associations of Reduced Estimated Glomerular Filtration Rate with Concurrent Chronic Kidney Disease Complications
C. Barrett Bowling, Lesley A. Inker, Orlando M. Gutiérrez, Richard M. Allman, David G. Warnock, William McClellan, and Paul Muntner
See related editorial on on page 2729.

2829 Serum Free Light Chains and the Risk of ESRD and Death in CKD

2838 Outcome Differences across Transplant Centers: Comparison of Two Methods for Public Reporting
Stefanos Zenios, Glenn Atias, Charles McCulloch, and Constantia Petrou
See related editorial on page 2732.

2846 Low-Molecular-Weight Proteins as Prognostic Markers in Idiopathic Membranous Nephropathy
Jan A.J.G. van den Brand, Julia M. Hofstra, and Jack F.M. Wetzels

ESRD and Chronic Dialysis

2854 Kinetic Model of Phosphorus Mobilization during and after Short and Conventional Hemodialysis
Baris U. Agar, Alp Akonur, Ying-Cheng Lo, Alfred K. Cheung, and John K. Leypoldt

2861 Novel Lipoprotein Subfraction and Size Measurements in Prediction of Mortality in Maintenance Hemodialysis Patients
See related editorial on page 2738.

Mineral Metabolism/Bone Disease

2871 Fibroblast Growth Factor 23, Cardiovascular Disease Risk Factors, and Phosphorus Intake in the Health Professionals Follow-up Study
Orlando M. Gutiérrez, Myles Wolf, and Eric N. Taylor
See related editorial on 2735.

Renal Transplantation

2879 Serum Erythropoietin Level and Mortality in Kidney Transplant Recipients
Miklos Z. Molnar, Adam G. Tabak, Ahsan Alam, Maria E. Czira, Anna Rudas, Akos Ujszaszi, Gabriella Beko, Marta Novak, Kamyar Kalantar-Zadeh, Csaba P. Kovesdy, and Istvan Mucsi

2887 Living Kidney Donors Ages 70 and Older: Recipient and Donor Outcomes
Jonathan C. Berger, Abimereki D. Muzaale, Nathan James, Mohammed Hoque, Jacqueline M. Garonzik Wang, Robert A. Montgomery, Allan B. Massie, Erin C. Hall, and Dorry L. Segev
Infectious Complications in Kidney-Transplant Recipients Desensitized with Rituximab and Intravenous Immunoglobulin

Joseph Kahwaji, Aditi Sinha, Mieko Toyoda, Shili Ge, Nancy Reinsmoen, Kai Cao, Chih-Hung Lai, Rafael Villicana, Alice Peng, Stanley Jordan, and Ashley Vo

Erratum


On the Cover

Whats the diagnosis? Lithium-induced chronic kidney disease occurs most commonly after 10–20 years of lithium therapy. Accumulation of lithium in cells of the distal nephron and early collecting duct via epithelial sodium channel is most likely responsible for the chronic nephrotoxic effects. Histologically, the injury is characterized by the presence of chronic tubulointerstitial nephritis, with interstitial fibrosis, tubular atrophy, and dilatation of distal tubules and collecting ducts that eventually leads to formation of small cysts within both, cortex and medulla. The findings are, however, somewhat non-specific and the diagnosis of lithium-induced nephropathy should be made if tubulointerstitial nephritis is found in a patient on long-term lithium therapy and other causes of renal disease have been excluded; magnetic resonance imaging can also be very helpful in establishing the diagnosis. (Image and text provided by Dr. Vanesa Bijol, Brigham and Women’s Hospital)